ArticleNPJ breast cancer2022

Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer.

Selena J An et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.